Poolbeg Pharma PLC (LON:POLB – Get Free Report) shares hit a new 52-week high during trading on Tuesday . The company traded as high as GBX 5.80 and last traded at GBX 5.55, with a volume of 5824547 shares changing hands. The stock had previously closed at GBX 5.04.
Analyst Ratings Changes
Separately, Shore Capital Group reiterated a “house stock” rating on shares of Poolbeg Pharma in a research note on Tuesday.
Read Our Latest Report on Poolbeg Pharma
Poolbeg Pharma Price Performance
Poolbeg Pharma (LON:POLB – Get Free Report) last posted its quarterly earnings data on Tuesday, April 28th. The company reported GBX (0.94) earnings per share for the quarter. On average, research analysts forecast that Poolbeg Pharma PLC will post -0.68 EPS for the current year.
About Poolbeg Pharma
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.
Read More
- Five stocks we like better than Poolbeg Pharma
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
